×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARQT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/2
10:57 am
arqt
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics: Behind The Big Rally [Seeking Alpha]
11/28
08:04 am
arqt
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
Low
Report
Arcutis Biotherapeutics (NASDAQ:ARQT) was given a new $37.00 price target on by analysts at Mizuho.
11/27
01:47 pm
arqt
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
Low
Report
Tori Spelling And Daughter Stella Open Up About Struggles With Eczema [Forbes]
11/17
08:00 am
arqt
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
Medium
Report
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
11/13
08:38 am
arqt
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]
Low
Report
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis [Yahoo! Finance]
11/13
08:00 am
arqt
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Low
Report
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
11/12
04:26 am
arqt
Arcutis Biotherapeutics (ARQT): Assessing Valuation After First Profitable Quarter and Raised Growth Outlook [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT): Assessing Valuation After First Profitable Quarter and Raised Growth Outlook [Yahoo! Finance]
11/7
04:24 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
10/28/2025
08:30 am
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
18.3%
arcutis biotherapeutics, inc. - common stock
8/6/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-8.1%
arcutis biotherapeutics, inc. - common stock
5/6/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
-4.3%
arcutis biotherapeutics, inc. - common stock
2/25/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
8.4%
arcutis biotherapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
05:24 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Dec 01 Filed by: Matsuda Masaru
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Dec 01 Filed by: Matsuda Masaru
12/3
05:24 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Dec 01 Filed by: Welgus Howard G.
Medium
Report
Form 4 Arcutis Biotherapeutics, For: Dec 01 Filed by: Welgus Howard G.
12/1
04:07 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
Medium
Report
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
12/1
04:07 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
Medium
Report
Form 144 Arcutis Biotherapeutics, Filed by: Matsuda Masaru
11/25
06:27 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Nov 24 Filed by: LIN SUE-JEAN
Low
Report
Form 4 Arcutis Biotherapeutics, For: Nov 24 Filed by: LIN SUE-JEAN
11/24
06:45 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Nov 21 Filed by: Watanabe Todd
Low
Report
Form 4 Arcutis Biotherapeutics, For: Nov 21 Filed by: Watanabe Todd
11/24
04:02 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: LIN SUE-JEAN
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: LIN SUE-JEAN
11/24
03:56 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 10-K Arcutis Biotherapeutics, For: Dec 31
33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
TOP News Decliners
3/16
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
-16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: